Price$63.61-0.89 (-1.39%)
01:30 PM07:45 PM
News · 26 weeks81+20%
2026-04-192026-10-11
Mix4590d
- Insider19(42%)
- SEC Filings13(29%)
- Other8(18%)
- Earnings2(4%)
- Offering2(4%)
- Leadership1(2%)
Latest news
25 items- SECSEC Form 8-K filed by Vaxcyte Inc.8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior NotesSAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00 per share, pre-funded warrants to purchase 400,000 shares of common stock at a public offering price of $63.999 per pre-funded warrant and $575 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the "notes"). These offerings included the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock at the public offer
- SECSEC Form 424B5 filed by Vaxcyte Inc.424B5 - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form 424B5 filed by Vaxcyte Inc.424B5 - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form FWP filed by Vaxcyte Inc.FWP - Vaxcyte, Inc. (0001649094) (Subject)
- PRVaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesSAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the "notes"). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-fu
- SECSEC Form 424B5 filed by Vaxcyte Inc.424B5 - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form 424B5 filed by Vaxcyte Inc.424B5 - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form 305B2 filed by Vaxcyte Inc.305B2 - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesSAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- PRBiotech Brainiacs and BreakthroughsDENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ:ALEC) and NeOnc Technologies (NASDAQ:NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ:PCVX) delivers a potentially market-shifting Phase 3 vaccine readout. Alector Lands A $1.27 Billion Genentech Deal Alector (NASDAQ:ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential milestone payments of up to $1.17 billion, and tiered
- SECSEC Form 8-K filed by Vaxcyte Inc.8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateVAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 Serotypes Shared with PCV20 and/or PCV21 Met Noninferiority Criterion at >0.667 Threshold; All Three Serotypes Unique to VAX-31 and Cross-Reactive Serotype 20B Met Superiority Criterion Prespecified Primary Immunobridging Endpoint: Across All 321 Serotype Comparisons, VAX-31 Met Noninferiority Criterion at >0.667 Threshold in Adults Aged 18-49 Compared with Adults Aged 50-64 Prespecified Primary Safety Endpoint: VAX-31 Was Well Tolerated and Demonstrated a Safety Profile S
- PRVaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateSAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX1005. A live webcast of th
- INSIDEREVP, Chief Scientific Ofc, COO Wassil Jim exercised 2,250 shares at a strike of $5.35 and sold $127,513 worth of shares (2,250 units at $56.67) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant covered exercise/tax liability with 17,056 shares, decreasing direct ownership by 4% to 429,902 units (SEC Form 4) to satisfy tax liability4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERPRESIDENT AND CFO Guggenhime Andrew covered exercise/tax liability with 7,155 shares, decreasing direct ownership by 7% to 95,316 units (SEC Form 4) (tax withholding)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERChief Technical Ops Officer Dhaliwal Harpreet S. covered exercise/tax liability with 7,651 shares, decreasing direct ownership by 10% to 68,085 units (SEC Form 4) (withholding obligation)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSVP, Finance & CAO Cowan Elvia covered exercise/tax liability with 1,327 shares, decreasing direct ownership by 5% to 27,860 units (SEC Form 4) to cover taxes4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDEREVP, Chief Scientific Ofc, COO Wassil Jim sold $163,863 worth of shares (2,715 units at $60.35) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,459 shares, decreasing direct ownership by 5% to 145,435 units (SEC Form 4) (for tax liability)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERChief Medical Officer Jodar Luis was granted 52,632 shares (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jodar Luis3 - Vaxcyte, Inc. (0001649094) (Issuer)
PCVX FAQ
7 questionsWhat does Vaxcyte Inc. do?
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020...Where does PCVX stock trade?
Vaxcyte Inc. (PCVX) is listed on NASDAQ.What sector and industry is PCVX in?
Vaxcyte Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vaxcyte Inc. go public?
Vaxcyte Inc. (PCVX) completed its IPO in 2020.What are analysts saying about PCVX?
Vaxcyte Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-01-07. Recent price targets cluster around $3800.00.What companies are similar to PCVX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCVX side-by-side with any of them on Quantisnow.How can I track PCVX on Quantisnow?
Quantisnow aggregates Vaxcyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCVX to receive live email and push alerts on every new disclosure.